Atstock Productions
- Knight Therapeutics (TSX:GUD:CA) has entered into a definitive asset purchase agreement with Endo Operations and Paladin Pharma, to acquire the Paladin business.
- At closing, Knight will pay an upfront payment of $120 million in cash, including inventory with a value of $20 million.
- In addition, Knight may pay future contingent payments of up to $15 million upon achieving certain sales milestones.
- In 2024, Paladin generated revenues of $70 million excluding products that Paladin has stopped commercializing or is in the process of discontinuing.
More on Knight Therapeutics Inc.
Source link
